DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials

DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.